Year: 2026

Results from the Phase 3 VELA clinical trials in adults with moderate-to-severe hidradenitis suppurativa (HS) show that clinical responses continue to improve to Week 40, with 62% of patients treated with sonelokimab (SLK) achieving HiSCR75 and up to 32% of patients achieving HiSCR100  An analysis of different hallmark lesions of HS shows that up to 25% of patients achieved inflammatory remission at Week 40, defined as a 100% reduction in abscesses (A100), nodules (N100) and draining tunnels (DT100) Patients treated with SLK also showed substantial improvements in HiSQOL items at week 40 versus baseline, ranging from 41% (pain), to 54% (walking, getting dressed) to 62% (down or depressed) Up to 43% of patients achieved an at least 3-point improvement from baseline in the worst skin pain NRS, while 65% of patients achieved an improvement...

Envudeucitinib achieved robust PASI responses by Week 16, with significant continued improvements by Week 24 in PASI 90 (68.0%, 62.1%) and PASI 100 (41.0%, 39.5%)Quality‑of‑life improvements and itch relief emerged ahead of PASI 90 skin clearance, and clear or almost clear scalp psoriasis emerged by Week 4, highlighting envudeucitinib’s early onset and broad clinical benefitEnvudeucitinib demonstrated a favorable safety and tolerability profile consistent with the Phase 2 programResults presented as a late-breaking oral presentation at the 2026 American Academy of Dermatology (AAD) Annual MeetingConference call and webcast scheduled for March 29, 2026, at 5:00 pm MDT / 7:00 pm EDTSOUTH SAN FRANCISCO, Calif., March 28, 2026 (GLOBE NEWSWIRE) — Alumis Inc. (Nasdaq: ALMS), a late-stage biopharmaceutical company developing...

Press Release Decision of the US District Court for the Southern District of New York in the TriZetto re-trial Paris, France – March 28, 2026 – Atos Group notes that on 27 March 2026 the United States District Court for the Southern District of New York issued its pre-judgment decision in the litigation between Syntel and Cognizant and its subsidiary TriZetto. The Court ordered Syntel to pay 236,9 million dollars (204,1 million euros1) to Cognizant/TriZetto. This amount is composed as follows:In this decision, the judge confirmed the jury’s findings, delivered on 30 June 2025, of compensatory damages of US $69,977,813.The Court also reduced the previously awarded punitive damages to US $139,955,626 (2x compensatory damages), subject to TriZetto’s acceptance of the reduction (failing which a new trial on punitive damages will be ordered)....

Investigational ZORYVE® (roflumilast) cream 0.05% was well tolerated with safety findings consistent with prior pediatric experience in the INTEGUMENT program ZORYVE cream improved signs and symptoms of mild to moderate atopic dermatitis in infants aged 3 months to less than 24 months over four weeks Caregivers reported rapid improvement in itch in as little as 10 minutes in nearly half of infants Results from additional studies across the ZORYVE portfolio being presented in three poster presentationsWESTLAKE VILLAGE, Calif. and DENVER, March 28, 2026 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced new data from the INTEGUMENT-INFANT Phase 2 trial demonstrating that ZORYVE® (roflumilast)...

Featured presentation highlights positive BroADen Phase 1b atopic dermatitis trial results supporting KT-621’s compelling oral profile Parallel Phase 2b trials, BROADEN2 in atopic dermatitis and BREADTH in asthma, ongoing with data expected by mid-2027 and late-2027, respectively WATERTOWN, Mass., March 28, 2026 (GLOBE NEWSWIRE) — Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the positive results from the BroADen Phase 1b atopic dermatitis (AD) clinical trial of KT-621, its first-in-class, oral STAT6 degrader, were featured in a late-breaking oral presentation at the American Academy of Dermatology (AAD) Annual Meeting. The meeting is being held March 27-31, 2026, in Denver, CO. “We’re...

AAD: new results from Sanofi’s amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research sessionAcross the COAST 1, COAST 2, and SHORE phase 3 studies, amlitelimab, dosed either Q4W or Q12W, showed progressively increasing efficacy, with no evidence of plateau at Week 24 across endpoints Data reinforce potential for Q12W dosing from the startParis, March 28, 2026. Positive results from three phase 3 studies of amlitelimab, a fully human non-T cell depleting monoclonal antibody that selectively targets OX40-ligand (OX40L), in moderate-to-severe atopic dermatitis (AD) as a monotherapy and in combination with topical therapies, showed improvements in skin clearance and disease severity with amlitelimab treatment compared to placebo in patients aged 12 years and older. The studies, COAST 1 (clinical study...

Rocket Lab Electron Launch For European Space AgencyRocket Lab Electron Launch For European Space AgencyMAHIA, New Zealand, March 28, 2026 (GLOBE NEWSWIRE) — Rocket Lab Corporation (Nasdaq: RKLB) (“Rocket Lab” or the “Company”), a global leader in launch services and space systems, today successfully completed its first dedicated launch for the European Space Agency (ESA), demonstrating Electron’s key and growing role in supporting space agency missions with repeatable and reliable commercial launch services. The launch, named “Daughter Of The Stars”, lifted off from Rocket Lab Launch Complex 1 in New Zealand on March 28th at 10:14 pm NZT to successfully deliver ESA’s “Celeste” mission to orbit: the first two spacecraft of a satellite navigation demonstration mission in low Earth orbit at 510 km. ESA’s Celeste mission will...

Vivoryon Therapeutics N.V. Provides Update on Growing Body of Evidence Validating Glutaminyl Cyclases as Promising Targets in DKD at World Congress of Nephrology Halle (Saale) / Munich, Germany, March 28, 2026 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company developing small molecule medicines for inflammatory and fibrotic disorders, with a primary focus on kidney diseases, today announced that new data analyses from the Company’s varoglutamstat Phase 2 program were presented at the World Congress of Nephrology (WCN) held in Yokohama, Japan, March 28-31, 2026. “We are very pleased with the opportunity to share our consistently compelling results with world leading experts in the kidney space at WCN, the International Society of Nephrology’s flagship event,” said Frank Weber,...